Cel-Sci/$CVM

1D1W1MYTD1Y5YMAX

About Cel-Sci

CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.
Ticker
$CVM
Sector
Health
Primary listing
AMEX
Employees
44
Headquarters
Vienna, United States
Website
cel-sci.com

Cel-Sci Metrics

BasicAdvanced
$26M
-
-$2.57
0.56
-

Cel-Sci News

AllArticlesVideos

Leading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients

Business Wire1 month ago

CEL-SCI Corporation Announces Pricing of Offering

Business Wire3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.